Laila Keith
Longwood Fund is a healthcare venture capital firm that creates and invests in science-based companies that develop novel solutions for important medical problems. The firm, founded in 2010, is based in Boston, Massachusetts, and focuses its investments in the healthcare, pharmaceutical, and biotechnology sectors. Longwood's mission is to identify technologies and found companies that will advance new therapeutics that can make a difference in the lives of patients worldwide while also creating significant value for investors. The company hosts semi-annual industry meetings with thought leaders and decision-makers to discuss collaboration and innovation. Longwood has made 68 investments, with its latest investment being in SEQL as part of its Unattributed VC on July 3, 2024. In this paragraph, we will explore the topic of how to invest in the Longwood Fund, including the firm's investment strategy, areas of focus, and the process for potential investors to get involved.
What You'll Learn
Longwood Fund's investment criteria
Longwood Fund is a healthcare venture capital firm that creates and invests in science-based companies that develop novel solutions for important medical problems. The fund's mission is to identify technologies and found companies that will advance new therapeutics that can make a difference in the lives of patients worldwide and create significant value for investors. Longwood Fund prefers to invest in the healthcare, pharmaceutical, and biotechnology sectors.
In addition to its investment criteria, Longwood Fund also hosts semi-annual industry meetings with thought leaders and decision-makers across government, pharma, biotech, and academia. These meetings provide opportunities for collaboration and access to innovation, with the goal of driving innovation forward and accelerating the translation of discoveries into medicines. Longwood Fund's partners have co-founded 25 companies with over 20 launched or marketed therapies and more than two dozen clinical assets, all focused on helping patients.
Longwood Fund's latest investment was in SEQL as part of their Unattributed VC on July 3, 2024. The fund has made a total of 68 investments and has 15 portfolio exits, with its latest portfolio exit being Pyxis Oncology on October 8, 2021. Longwood Fund has 7 funds, including Longwood Fund VI.
Funding a TD Direct Investing Account: Simple Steps
You may want to see also
Longwood Fund's portfolio companies
Longwood Fund is a healthcare venture capital firm that founds, manages, and builds healthcare companies. The fund's mission is to identify technologies and found companies that will advance new treatments that can make a difference in the lives of patients worldwide and create significant value for investors. Longwood Fund creates and invests in science-based companies that develop novel solutions for important medical problems.
Longwood Fund has made 68 investments and has 15 portfolio exits. The fund's latest investment was in SEQL as part of their Unattributed VC on 3 July 2024. The fund has also invested in Progentos Therapeutics, Engrail Therapeutics, Tome Biosciences, and Sitryx Therapeutics.
Longwood Fund is dedicated to creating and investing in novel healthcare companies that develop important treatments to help patients while generating significant value for investors. The fund has a long history of launching and building important life science companies while providing operational leadership and strategic guidance.
Low-Cost Trading Funds: Smart Investment, Smart Returns
You may want to see also
Longwood Fund's exits
Longwood Fund is a healthcare venture capital firm that creates and invests in science-based companies that develop novel solutions for important medical problems. The fund has a particular interest in the healthcare, pharmaceutical, and biotechnology sectors.
Longwood has a history of launching and building life science companies, providing operational leadership and strategic guidance. The fund has co-founded 25 companies with over 20 launched or marketed therapies and more than two dozen clinical assets, all focused on helping patients.
Longwood Fund has made 68 investments and has 15 portfolio exits as of October 2021. One notable exit was Pyxis Oncology on October 8, 2021. The fund has also made investments in companies such as Engrail Therapeutics, Tome Biosciences, and Sitryx Therapeutics.
Longwood's partners include world-renowned scientific leaders and co-founders, often taking on active roles in building the companies they invest in. The fund hosts semi-annual industry meetings with thought leaders and decision-makers from government, pharma, biotech, and academia to discuss collaboration and innovation.
Index Funds: When to Start Investing for Maximum Returns
You may want to see also
Longwood Fund's team
Longwood Fund is a healthcare venture capital firm that creates and invests in science-based companies that develop novel solutions for important medical problems. The Longwood team has a long history of launching and building important life science companies while providing operational leadership and strategic guidance. Partners at Longwood have co-founded 25 companies with over 20 launched or marketed therapies, and more than two dozen clinical assets, all focused on helping patients.
The Longwood Fund team consists of 42 members, including Chief Financial Officer Christoph Westphal Ph.D, Co-Founder & General Partner Aleks Radovic-Moreno Ph.D, and three partners: Christoph Westphal, Michelle Dipp, and Rich Aldrich. Westphal and Dipp are Cambridge-based executives at GlaxoSmithKline, while Aldrich runs RA Capital Management, a Back Bay investment firm. Westphal is also the chief executive of Sirtris and a senior vice president of Glaxo's Centre for Excellence in External Drug Discovery.
Longwood Fund has a strong track record of successful investments, with their latest investment being in SEQL as part of their Unattributed VC on July 3, 2024. They have made a total of 68 investments and have 15 portfolio exits, with their latest being Pyxis Oncology on October 8, 2021. The firm is dedicated to creating and investing in novel healthcare companies, particularly in the healthcare, pharmaceutical, and biotechnology sectors. They actively seek new investments and have a preference for early-stage life sciences start-ups.
IRA Investment Options: Mutual Funds or ETFs?
You may want to see also
Longwood Fund's co-investors
Longwood Fund is a healthcare venture capital firm that identifies, founds, manages, and builds science-based healthcare companies. Longwood Fund's mission is to identify technologies and found companies that will advance new treatments that can make a difference in the lives of patients worldwide and create significant value for investors.
Longwood Fund has 136 co-investors, including:
- DC Investment Partners
- RA Capital Management
- Astellas Venture Management
- Institutional Research Group
- Morningstar Institutional Equity Research
- Alexandria Venture Investments
- Eli Lilly
- Engrail Therapeutics
- Abrdn
- Tome Biosciences
- Sitryx Therapeutics
The Social Security Trust Fund: Where is it Invested?
You may want to see also
Frequently asked questions
The Longwood Fund is a venture capital firm that founds, manages, and builds science-based companies that develop novel solutions for important medical problems.
The Longwood Fund finances and invests in science-based companies that develop novel solutions for medical problems. The fund prefers to invest in the healthcare, pharmaceutical, and biotechnology sectors.
The Longwood Fund is based in Boston, Massachusetts, United States.
You can contact the Longwood Fund via email at [email protected] or by phone. Their headquarters address is 800 Boylston Street Suite 1555, Boston, Massachusetts, 02199.
